Drug intelligence / Profile preview

TT-00973-MS

Development stage: Phase 1
Lead developer: TransThera Biosciences
Modality: Small Molecules
Administration: Oral

Overview

TT-00973-MS is a small molecule dual inhibitor of AXL and FLT3 being developed by TransThera Biosciences. It is currently in Phase 1 clinical trials for the treatment of advanced solid tumors. The drug is administered orally in tablet form. A modified 3+3 design is being used to determine the maximum tolerated dose (MTD) during the dose escalation period, with further expansion planned to enroll additional patients to evaluate safety and preliminary efficacy.

Targets

AXL (AXL receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)

Beyond the preview

Go deeper on TT-00973-MS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TT-00973-MS.

Explore the full profile